The First Affiliated Hospital Of Xiamen University

This study tests whether giving a bone marrow-protecting drug (trilaciclib) before chemotherapy (sacituzumab tirumotecan) can reduce serious side effects like low white blood cell counts in people with advanced EGFR-mutant lung cancer that no longer responds to standard targeted …

This early-stage study tests a new treatment called GB5005 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has returned or stopped responding to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize…

This study tests a combination of three drugs (venetoclax, chidamide, and azacitidine) in adults whose acute myeloid leukemia has returned or not responded to prior treatment. The goal is to see if this mix can safely achieve remission. About 30 participants will receive the trea…

This study is testing a new imaging tracer that targets a protein called DLL3, found on some neuroendocrine cancer cells. The goal is to see if this special PET/CT scan can find tumors better than standard scans. About 60 adults with suspected or confirmed neuroendocrine cancer w…

This study tests a new type of PET scan (68Ga-NK224) to see if it can accurately measure PD-L1 levels in tumors without needing a biopsy. About 100 adults with cancer will get the scan, and the results will be compared to standard tissue tests. The goal is to find a less invasive…

This study aims to see if a new type of PET scan, called 68Ga-XACP3 PET/CT, can find prostate cancer tumors as well as or better than the current standard scan (68Ga-PSMA PET/CT). About 60 adults with newly diagnosed, suspected recurrent, or previously treated prostate cancer wil…

This study is testing whether a special PET scan can predict how well a targeted cancer drug works in people with advanced lung cancer. About 50 adults with metastatic non-small cell lung cancer will get the scan before and during treatment. The goal is to see if changes in the s…